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Purpose. To evaluate retrospectively the impact of diﬀusion weighted imaging (DWI) and (3D) hydrogen 1 (1H) MR-spectroscopy
(MRS) on the detection of prostatic cancer in comparison to histological examinations. Materials and Methods. 50 patients with
suspicion of prostate cancer underwent a MRI examination at a 1.5T scanner. The prostate was divided into sextants. Regions
of interest were placed in each sextant to evaluate the apparent diﬀusion coeﬃcient (ADC)-values. The results of the DWI as
well as MRS were compared retrospectively with the ﬁndings of the histological examination. Sensitivity and speciﬁcity of ADC
and metabolic ratio (MET)—both separately and in combination—for identiﬁcation of tumor tissue was computed for variable
discrimination thresholds to evaluate its receiver operator characteristic (ROC). An association between ADC, MET and Gleason
score was tested by the non-parametric Spearman ρ-test. Results. The average ADC-value was 1.65±0.32mm2/s × 10−3 in normal
tissue and 0.96±0.24 mm2/s × 10−3 in tumor tissue (mean ± 1S D ) .M E Tw a s0 .418 ± 0.431 in normal tissue and 2.010 ± 1.649
in tumor tissue. The area under the ROC curve was 0.966 (95%-conﬁdence interval 0.941–0.991) and 0.943 (0.918–0.968) for
DWI and MRS, respectively. There was a highly signiﬁcant negative correlation between ADC-value and the Gleason score in the
tumor-positive tissue probes (n = 62, ρ =− 0.405, P = .001). MRS did not show a signiﬁcant correlation with the Gleason score
(ρ = 0.117, P = .366). By using both the DWI and MRS, the regression model provided sensitivity and speciﬁcity for detection
of tumor of 91.9% and 98.3%, respectively. Conclusion. The results of our study showed that both DWI and MRS should be
considered as an additional and complementary tool to the T2-weighted MRI for detecting prostate cancer.
1.Introduction
In Europe as well as in the United States prostate cancer is
a very common and frequent cancer in males. According to
the American Cancer Society, it is the third leading cause of
cancer-related death in men. In 2007, 218,890 new cases are
assumedtobediagnosedandabout27,050personsestimated
to die due to this disease [1]. In Europe the incidence of the
prostatecancerisapproximately30per100000menandalso
the third frequent cause of death after lung and colorectal
cancer [2].
Several diagnostic methods have been applied in recent
years to detect the malignant changes within the prostate.
The transrectal ultrasound (TRUS) of the prostate is the
primarily used method worldwide, besides the laboratory
modus operandi. It is used not only to gain the ﬁrst
impression of the organ, but also to guide prostate biopsies,
if necessary [3]. Another commonly used method is MR
imaging of the prostate using an endorectal coil and a pelvic
phased-array coil, in which the malignant sites usually show
a hypointense signal compared to the normal hyperintense
peripheral zone [4]. In contrast to the TRUS, the patients
have to undergo longer examinations, but the local staging
as well as the assessment of the surrounding tissues and
organs has shown a better sensitivity using the MRI than
the aforementioned [5]. Recent studies also showed that the2 Radiology Research and Practice
MR-guided biopsies of the prostate are possible and are of
the same histopathologic quality as specimens obtained with
a TRUS guided biopsies [6].
Over the past few years, however, other MRI tech-
niques have been developed to improve the diagnostic
accuracy. A number of studies have shown that the three-
dimensional 1H-spectroscopy of the prostate can ameliorate
the anatomical and morphological situation as well as the
characterization of the prostate cancer [7].
Diﬀusion weighted MR Imaging (DWI) is a technique
to evaluate the molecular diﬀusion based on the Brownian
motion of the spins in biological tissues. DWI provides
information on both the perfusion and the diﬀu s i o ni na n y
organ to characterize abnormal tissue changes within the
sites. This method can be regarded as an additive method
to T2-weighted MRI by developing image contrast through
“apparent diﬀusivity.” Diﬀusion weighted MRI is showing
potential for improving prostate cancer detection [8–10].
By adding the diﬀusion-weighted imaging to conventional
T2-weighted MR imaging, an improvement of detection
of prostate cancer was found [8], and diﬀusion-weighted
imaging at 3.0T has also showed reduced ADC values and
increased fractional anisotropy in prostate cancer [11]a s
well.
These diﬀerent methods were combined and compared
in several studies as well, especially the MR spectroscopy
and the DW imaging. It has been shown that there is
a positive correlation between ADC values and the ratio
for choline and creatine to citrate in men with elevated
prostate-speciﬁc antigen (PSA) levels [12]. Another study
showed that if an examined voxel contained ≥70% tumor,
the combined usage of MR spectroscopy and DW imaging
increased the speciﬁcity in detecting prostate cancer, while
thesensitivitycomparedtoMRspectroscopyorDWimaging
alone retained [13]. Recently, Mazaheri et al. has reported
a more precise study about the same issue, using the three-
dimensional (3D) hydrogen 1 (1H) MR spectroscopy and the
DW imaging. Also in this study, it could be shown that the
combination of these two had a signiﬁcant improvement in
diﬀerentiation from malignant and benign tissue [14].
The aim of this study was to apply both (3D) hydrogen
1( 1H) MRS and DWI to the prostate and to determine
the Choline-Citrate ratios and the ADC values of healthy
tissue and prostate cancer and to compare retrospectively
the results with histology, by means of the Gleason-Score,
in patients with questionable prostate cancer. Herewith, we
hopetoassessthepotentialswithregardtothediﬀerentiation
of cancer, and to determine the ADC values and the
Choline-Citrate ratio of healthy tissue and prostate cancer in
comparison to histology.
2.MaterialsandMethods
2.1. Study Population. In this study, 50 patients with clin-
ical suspicion of prostate cancer underwent a combined
endorectal-body-phased-array MRI at a 1.5T MRI scanner.
The mean age of the examined patients was 61.8 years,
with the range of 44 to 78 years. The study protocol was
approved by the local Ethics Committee, and informed
consent was obtained from all patients. From all patients,
blood samples were taken to ascertain the prostate speciﬁc
antigen (PSA) levels. The prerequisite for the examination
was that the patients would undergo a transrectal ultrasound
(TRUS)andbiopsyorprostatectomythereafter.Patientswith
prior hormonal, surgical, or irradiation therapies as well as
previous biopsies within 12 weeks prior to the examination
date were excluded.
2.2.MRIImagingProtocol. Allexaminationswereperformed
on a 1.5T scanner (Symphony; Siemens Medical Solutions,
Erlangen, Germany) with a combination of an endorectal
coil (MRInnervu; Medrad, Indianola, USA) and a body and
spine panoramic array. No contrast medium was used. For
the morphological evaluation of the prostate including the
lymph node status of the pelvis, a T1-weighted spin echo
(SE) sequence was used. To evaluate prostatic changes a
T2-weighted fast spin echo (FSE) sequence in transversal,
coronal, and sagittal orientation was performed (Table 1).
2.3. Diﬀusion-Weighted Imaging. Based on the T2w images
ad i ﬀusion weighted (DW) spin echo-planar sequence was
generated in transversal orientation to include the whole
prostateusingthefollowingparametersalsousingtheabove-
mentioned coil combination: TR 3100ms; TE 88ms; FOV
180 × 180mm; matrix 128 × 128mm; Slice thickness 4mm;
intersection gap 0mm; voxel size 1.8 × 1.5 × 4mm; b-
factors 50, 400, 800s/mm2; 20 slices. The duration of the
examination was about 4 to 6 minutes. For DW imaging the
above-mentioned coil combination was used.
The ADC is given by the following equation:
S(I) = S(0)e −(bi ·ADC),( 1 )
where S(I) was the signal intensity measured on the ith
b-factor image, and b1 was the corresponding b-factor. S0
estimates the signal intensity for a b-factor of 0s/mm2, that
is, without the noise induced by the MR measurement [15].
A starting b-value of 50s/mm2 was used to suppress vascular
signal in the initial T2 weighted EPI image. The diﬀusion
weighting was performed with a trace weighted sequence
type (3 orthogonal directions).
According to this equation, ADC-maps were generated
using the software attached to the scanner on the basis of
a voxelwise calculation and were interpolated to a 256 ×
256mm matrix.
2.4. 3D-1H MR Spectroscopic Imaging. The spectroscopic
imaging was performed with the spectroscopic software
provided by the MR scanner (Symphony; Siemens Medical
Solutions, Erlangen, Germany), using only the endorectal
coil. This software acquires data with the point-resolved
spatially localized spectroscopy. By using spectral-spatial
pulses, choline, creatine, and citrate were excited within
the box. Water and lipids were suppressed with a shim
around the spectral box. The box was placed on the
transverse T2 weighted images, corresponding to the images
made beforehand. The magnetic ﬁeld homogeneities wereRadiology Research and Practice 3
Table 1
Sequence TR [ms] TE [ms] Slice Thickness [mm] FoV [mm] Matrix
T1 SE 765 14 5 350 215 ×215
T2 FSE transverse 3400 98 3 180 205 ×256
T2 FSE sagittal 3000 98 3 200 205 ×256
T2 FSE coronal 3000 98 3 200 205 ×256
automatically optimized by shimming algorithms provided
by the manufacturer.
The following parameters were acquired for the MR
spectroscopy: TR 700ms; TE 120ms; Flip angle 90◦;n u m b e r
of signal acquired = 1; spectral width = 1300Hz; number of
points = 512; FOV 80 × 80 × 80mm3, and phase-encoding
steps = 16×8×8. The voxel volume was 6.7×6.7×6.7mm 3;
SNR 100 csi-ce. The duration of the whole MR spectroscopy
was about 11.46 minutes.
The evaluation of the spectral data was made by utilizing
the manufacturer’s postprocessing software package. The
postprocessing included zero ﬁlling of the raw data in the
superior-inferior direction with a four-dimensional Fourier
transformation to yield a voxel volume of 300mm3,s p e c t r a l
apodization with a 2Hz Lorentzian function, base line
correction,peakregistration,andanalignmentof3D 1HMR
spectroscopic images to the transverse T2 weighted images.
The diameter of integration was 0.3ppm and was adjusted
for each voxel, just to reach the optimal broadening of each
spectral peak. Metabolic ratio maps of choline, creatine, and
citrate were generated: (choline + creatine)/citrate = MET
(metabolic ratio).
The whole time duration of the MRI examination
(incl. MRI, DWI and MRS) including time for patient
placement, coil placement, and localization of the prostate
was approximately 40 minutes. The image acquisition time
for the T1 SE, and the T2 FSE was 24 minutes and that for
the DWI were 5 minutes. The MRS lasted approximately 12
minutes.
2.5. MR Image Analyses. The morphological and possibly
pathological sites of the peripheral zone of the prostate
were retrospectively assessed with the T2 weighted images
by dividing the prostate into sextants, that is, the apex,
the mid-portion, and the base, each right and left side.
Then, the grey value of the pixel corresponded to the ADC
value [mm2/s × 10−3] since a pixel-to-pixel ADC map was
automatically calculated for each slice. The value itself was
calculated with the equation mentioned above. The regions
of interest (ROI) were then manually drawn in each sextant
of the prostate guided by the T2 weighted images. The
mean ROI size was 0.8mm2 (SD ± 0.56). Additionally,
metabolic ratio maps of choline, creatine, and citrate were
generated with the manufacturer’s software package for each
voxel, especially of suspect areas with the MR spectroscopy.
Voxels were classiﬁed as suspicious if the MET was >0.86
[16].
2.6. Biopsy/Histopathologic Analyses. All patients underwent
TRUS guided biopsies (in sextants: right and left sites of
the apical, the mid-partial and the basis of the prostate).
All biopsies were performed by urologists, and the biopsy
cores were labelled to specify the location of the biopsy.
Histopathologic analyses were made by the Institute of
Pathology for all biopsies of the prostate and the Gleason
scores were evaluated.
2.7. Statistical Analyses. The prostate was divided into 6
regions, that is, sextants: right/left apex, right/left midsec-
tion, and right/left base. Tissue probes from each site were
classiﬁed as “normal tissue” or “tumor tissue” according
to histopathology. Tumor tissue was further categorized
according to the Gleason score.
Univariate analysis of variance with ADC-values as
independent variable and tissue type (normal, tumor) and
as intersubject factors was used to compare the ADC value
between normal tissue and tumor and between diﬀerent
sextants.
Sensitivity and speciﬁcity of ADC-values for identiﬁca-
tion of tumor tissue were computed for variable discrimina-
tion thresholds to evaluate its receiver operator characteristic
(ROC). The histologically determined tissue type served
as gold standard. The area under the ROC curve was
computedasanoverallperformancemeasure.Anassociation
between the ADC value and Gleason score was tested by the
nonparametric Spearman ρ-test. The analysis was restricted
to the tumor-positive probes.
The statistical analyses were repeated with MET instead
of ADC-value as independent variable.
An eﬀect was considered statistically signiﬁcant if the
signiﬁcance level α = 0.05 was reached. All statistic
computations were performed using SPSS 15.0.1 for MS
Windows.
In order to test whether the combination of DWI and
MRS might improve the accuracy for detection of tumor
tissue compared to both DWI and MRS alone, stepwise
binary logistic regression was used with histopathology
(normal tissue, tumor) as dependent variable and ADC
values and MET as possible regressors (P for inclusion .05,
P for exclusion .10).
3. Results
The mean value of the prostate speciﬁc antigen (PSA)
taken from blood samples was 7.19μg/L (SD ± 5.2), where
the mean PSA level in patients with prostate cancer was
10.41μg/L (SD ± 5.1) and those in healthy ones 4.1μg/L (SD
± 4.2).
All MR examinations were performed successfully, and
although some images had susceptibility artifacts due to4 Radiology Research and Practice
(a)
(b)
Figure 1: Patient (45 y.o.) with prostate cancer (2.6cm): PSA-level
9.7μg/L (free PSA-level 14.56μg/L); Gleason-Score 4 + 5 = 9. In
the T2w image (a) the prostate cancer is demonstrated in the right
peripheral zone. In the correspondent ADC-map (b) the prostate
cancer is clearly shown as a hypointense area. The left peripheral
zone looks hyperintense on the T2w image, but the ADC-map
reveals the remaining healthy prostate tissue.
the endorectal coil, all images could be used for analyses.
The image acquisition time for the T1 SE, and the T2 FSE
was 24 minutes and that for the DWI were 5 minutes. The
MRS lasted approximately 11 minutes. As demonstrated in
Figure 1 the ADC maps show hyperintense in benign and
hypointense in malignant tissue in the peripheral zone.
Histopathology identiﬁed tumor tissue in 21 of the 50
patients (42%). All 6 sextants were inﬁltrated by the tumor
in 3 of these patients, 4 sextants in 3 patients, 3 sextants
in 5 patients, 2 sextants in 7 patients, and in 3 patients
tumor tissue was detected in only 1 sextant. Thus, in total
62 of the 300 tissue probes were tumor positive according to
histopathology (20.7%).
T h er a t eo ft u m o r - p o s i t i v et i s s u ep r o b e sr a n g e db e t w e e n
14% (left apex) and 28% (right midsection). However,
this variation was not signiﬁcant statistically (Pearson’s
“portmanteau” χ2 test: χ2 = 4.066, df = 5, P = .540).
The Gleason score of the tumor-positive tissue probes
was 5 in 3 sextants (4.8%), 6 in 16 sextants (25.8%), 7 in
22 sextants (35.5%), 8 in 6 sextants (9.7%), 9 in 11 sextants
(17.7%), and 10 in 4 sextants (6.5%).
Univariate analysis of variance revealed a highly signif-
icant diﬀerence of ADC-value between normal tissue and
tumortissue(F = 224.5,df = 1,P = .000),butnodiﬀerence
between the sextants (F = 0.138, df = 5, P = .983)
(Figure 2). There was also no signiﬁcant interaction eﬀect of
tissue type and sextants on ADC values (F = 0.356, df = 5,
P = .878). Averaged overall sextants, ADC-value was 1.65 ±
0.32 in normal tissue and 0.96 ± 0.23 in tumor tissue (mean
± 1 standard deviation).
MET also showed a highly signiﬁcant diﬀerence between
normaltissueandtumortissue(F = 198.4,df = 1,P = .000)
(Figure 2). The analysis of variance suggested a signiﬁcant
eﬀect of the sextants (F = 4.5, df = 5, P = .001) as well
as a signiﬁcant interaction eﬀect of tissue type and sextants
on MRS (F = 3.4, df = 5, P = .006). However, post hoc
comparison of MET between any pair of sextant did not
reveal any signiﬁcant eﬀect, neither in normal tissue nor in
tumor. Therefore, the sextants were not taken into account
in the further analyses. MET was 0.418 ± 0.431 in normal
tissue and 2.010 ± 1.649 in tumor tissue.
4. SensitivityandSpeciﬁcityof
DWI andMRSSeparatelyandCombined
Sensitivity and speciﬁcity of DWI and MRS were evaluated
separately using ROC analysis; a combined evaluation of
both methods was performed using a stepwise binary logistic
regression.
The ROC curves of DWI and MRS for identiﬁcation
of tumor tissue irrespective of the sextants are given in
Figure 3. The area under the ROC curve was 0.966 (95%-
conﬁdenceinterval0.941–0.991)and0.943(0.918–0.968)for
DWI and MRS, respectively. For DWI a sensitivity of 0.92
and a speciﬁcity of 0.93 were provided using discrimination
thresholdof1.208mm2/s ×10−3.Withathresholdproviding
the same sensitivity, that is, 0.92, MRS provided a speciﬁcity
of 0.85. With a threshold providing the same speciﬁcity, that
is, 0.93, MRS provided a sensitivity of 0.68.
Stepwise binary logistic regression included both DWI
(P<. 001) and MRS (P<. 001) for the diﬀerentiation
b e t w e e nn o r m a lt i s s u ea n dt u m o ri sd e m o n s t r a t e di n
Figure 4. The regression model classiﬁed 291 of the 300
probes correctly (97.0%). Only 4 of 238 normal tissue probes
were misclassiﬁed as tumor, and 5 of 62 tumor probes were
misclassiﬁedasnormal.Thus,theregressionmodelprovided
asensitivityandspeciﬁcityfordetectionoftumorof91.9and
98.3, respectively.
There was a highly signiﬁcant negative correlation
between DWI and the Gleason score in the tumor-positive
tissue probes (n = 62, ρ =− 0.405, P = .001) (Figure 5). In
contrast,MRS did not show a signiﬁcant correlation with the
Gleason score (ρ = 0.117, P = .366).
5. Discussion
However,the factthattheMRIoftheprostate mightbe more
advantageous than the transrectal ultrasound for staging the
cancer has also been discussed in the past (especially for T2Radiology Research and Practice 5
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Figure 2: Box-and-whisker plot of DWI (a) and MRS (b) as
a function of tissue type (normal tissue, tumor) and region of
interest(ROI).Outliers(1.5–3boxlengths)areindicated byacircle;
extreme values (>3 box lengths) are indicated by an asterix.
and T3 tumours) [17, 18]. The T2 weighted MRI images
of the prostate has been applied more often to improve the
validity of the staging in prostate cancer [19]. The prostate
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Figure 3: Receiver operator characteristic (ROC) curve of DWI (a)
and MRS (b) for diﬀerentiating tumor tissue from normal tissue.
The analysis included all 300 tissue probes irrespective of the ROI.
is one of the few organs in humans which can be examined
by MRI without any contrast media. Benign tissues in the
peripheral zone show hyperintense signals in T2 weighted
imaging, whereas malignant changes show hypointense
signals, of which the reason could be the cellular density as
well as the malfunction of the gland when the malignant
change had occurred. The cause of the decrease in diﬀusion
in malignant tissue has a histopathologic origin. Some
attributes are: hypercellularity, enlargement of the nuclei,6 Radiology Research and Practice
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Figure 4: Scatter plot of DWI versus MRS in normal tissue probes
and tumor-positive tissue probes.
hyperchromatism, and angulation of the nuclear contour,
which lead to a reduction of diﬀusional displacement of
watermolecules(AndersonJR.Muir’stextbookofpathology.
London, England: Edward Arnold 1985). Commonly, the
prostate produces 20 to 30% of the ejaculate secretions. In
patients with known prostatic cancer, the amount of the
ejaculate can be less than in healthy patients. However, this
is diﬃcult to determine since the secretions vary from 0.5 to
13mL.
Diﬀusion weighted MR imaging has been clinically
applied in several organs. Not only is it used to show the
aﬀected tissue after a stroke, it is also to diﬀerentiate brain
tumours[20,21]oralsovertebralmetastasesin,forexample,
prostate cancer [22]. In diﬀusion-weighted MRI (DWI) the
image contrast is determined by the random microscopic
motion of water protons, that is, the Brownian motion. The
diﬀusion can be measured in vivo by using the MRI because
of its sensitivity to motion. This sensitivity to motion can be
increased by the addition of strong magnetic ﬁeld gradient
pulses to the pulse sequence [23]. Shimofusa et al. applied
the DWI of the prostate with parallel imaging and with a
high b-value (b = 1000) for the ﬁrst time [8]. In this study
they have not used an endorectal coil, but the sensitivity as
well as speciﬁcity was higher than in other former studies
with endorectal coil [24–27]o rad y n a m i cs t u d y[ 28]. Since
then, several prostatic MR imaging modules were performed
toincreasethedetectabilityofcanceroustissue.Theresultsof
these studies demonstrate that the ADC value may provide
information about the malignant changes in the prostate
[29–31].
MR spectroscopy is a relatively new method in diagnos-
ing prostate cancer and has been a part of clinical routine
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Figure 5:ScatterplotofDWI(a)andMRS(b)versusGleasonscore
in tumor-positive tissue probes.
since 1980s. Since then, MR spectroscopy has been eﬀective
in improving the accuracy of MR imaging in prostate cancer
localization and staging [32–34]. In the healthy prostate,
malign and benign tissues can be diﬀerentiated by the MR
spectroscopy on the basis of the metabolic ratio of choline,
creatine, and citrate. The ratio is calculated by the equation
MET = (choline + creatine)/citrate. The MET is increased in
malign tissue whereas a lower MET can be found in benign
tissue [35, 36].
In this present study, 50 patients with suspected cancer
of the prostate were examined with the DW MRI and theRadiology Research and Practice 7
MR spectroscopy, and then compared retrospectively with
pathohistological results, especially with the Gleason score.
Two recent studies compared and analyzed the combined
usage of diﬀusion-weighted MRI and 1HM Rs p e c t r o s c o p y .
The one study examined 42 patients with prostate cancer
using a 2D chemical shift imaging and isotropic apparent
diﬀusion coeﬃcient (ADC) maps [13]. In this study the
regions of interest were drawn around the whole gland,
central gland, and the peripheral zone tumor. The mean
ADC value of the normal tissue in this study was 1.51mm2/s
× 10−3 [SD: ±0.27].
If the tumor was greater than 30% of the whole voxel
the mean ADC value was 1.19mm2/s × 10−3 [SD: ±0.24],
and if the tumor was greater than 70% of the whole voxel,
the value was 1.03mm2/s × 10−3 [SD: ±0.18]. The mean
MET in normal gland was 0.065 ± 0.052, whereas the value
was much higher in malignant tissues; 0.814 ± 2.202 in
tumor ≥30% of the voxel and 0.917±1.276 in tumor ≥70%,
respectively. The MET was signiﬁcantly higher (P<. 001)
and the ADC values were signiﬁcantly (P<. 006) lower
in tumor-containing voxel. The area under the ROC curves
using both the ADC and MET was 0.81, similar to only
MET (0.79), whereas ADC alone showed an area of 0.66 and
was inferior. An interesting point, however, is the signiﬁcant
improvement in speciﬁcity for the combination of ADC and
MET, when voxels containing 70% or tumor were considered
positive and cutoﬀs to achieve a 90% or greater sensitivity
were chosen [13].
The other study performed a retrospective measurement
of ADC and MET in 38 patients with prostatic cancer.
T h em e a nA D Cv a l u ea n dM E Tf o rm a l i g n a n tt i s s u ew e r e
1.39mm2/s × 10−3 [SD: ±0.23] and 0.92±0.32, respectively.
For benign tissue, the values were 1.69mm2/s × 10−3 [SD:
±0.24] and 0.73 ± 0.18 (P<. 001 for both). In this
study,areasunderthereceiveroperatingcharacteristiccurves
(AUCs) were performed to evaluate the accuracy. Obviously,
the combination of ADC and MET performed signiﬁcantly
better(AUC=0.85;P = .005)thanADCorMETalone(AUC
= 0.81 and AUC = 0.09, resp.) [14].
Analogue to these prior studies, our results of the ADC
values were signiﬁcantly lower (P<. 001) and the results
of the mean MET were signiﬁcantly higher (P<. 001)
for malignant prostatic tissues than for benign tissues. In
our study, the average ADC value in benign tissue was
1.65mm2/s × 10−3 [standard deviation (SD): ±0.32] and
t h a ti nm a l i g nt i s s u e s0 . 9 6m m 2/s × 10−3 [SD: ±0.24]. The
signiﬁcantly (P<. 001) lower ADC values in malign tissues
compared with the benign signify some promising results
in detecting the cancer. These results were similar to other
prior studies, although diﬀerent b-values (0 and 1000s/mm2
and 0, 300, 600s/mm2)[ 30, 37] were used in our study
(i.e., 50, 400, 800s/mm2). The cutoﬀ value of the mean
ADC value between cancerous and noncancerous tissue in
the present was at approximately 1.2mm2/s × 10−3,w h i c h
c a nb es e e no nt h eR O C - A n a l y s e s( Figure 3). Compared to
the aforementioned studies our results of the ADC value
for malignant tissue were remarkably lower. The MET of
malignant tissues showed an average value of 2.010 ± 1.649
in our study, and is signiﬁcantly higher than in healthy
tissues (0.418±0.431). This result can also be compared with
previous studies.
In this present study, a relatively larger number of
patients were examined than other studies. The combination
of DWI and MRS performed signiﬁcantly better in detecting
cancer in the periphery zone of the prostate than MRS
alone [14] in one study. In our study with 50 patients, the
combination of DWI and MRS seems also to have a better
accuracy in detecting cancerous tissue. The regression model
classiﬁed 291 of the 300 probes correctly (97.0%). Only 4 of
238 normal tissue probes were misclassiﬁed as tumor, and
5 of 62 tumor probes were misclassiﬁed as normal. Thus,
the regression model provided sensitivity and speciﬁcity for
detection of tumor of 91.9 and 98.3, respectively (Figure 5).
If the results were correlated with the Gleason-score,
there was a highly signiﬁcant negative correlation between
DWI and the Gleason score in the tumor-positive tissue
probes (n = 62, ρ =− 0.405, P = .001) (Figure 4). However,
MRS did not show a signiﬁcant correlation with the Gleason
score (ρ = 0.117, P = .366). One explanation could be that
in the present study the MET values were extracted using a
very short TR sequence (700ms) which keeps the scan time
tolerable but results in spectra that are fairly heavily T1-
weighted. Perhaps that is why the other groups [38]f o u n d
a weak correlation between Gleason and MET.
There are some problems and limitations in our study
like in other MR studies of the prostate. First limitations
are based on MR technique itself. Common artefacts for the
DWI are white pixel noise, low SNR (signal-to-noise ratio),
and susceptibility artefacts. In MR spectroscopy common
artefacts are lipid contamination and susceptibility artefacts.
These artefacts could be reduced by new methods in the
future. Second limitation is the discrepancy in voxel sizes
between the ADC map and the 3D 1HM Rs p e c t r o s c o p y .I n
the future new spectroscopic techniques with increased spa-
tial resolution without increasing the examination duration
[39] could be used to overcome this problem. The present
study was a retrospective analysis of the prostate cancer. The
malignant sites were known when analyzing the ADC map
and the MET. Chronic changes, such as chronic prostatitis
or atrophy of the gland itself, usually show similar changes
in MRI [4, 27] to prostatic cancer. Prospective studies
are another research task for succeeding studies with the
DWI and MRS, especially in patients with several negative
biopsies. The last limitation of this study was the usage of
sextant biopsy, since biopsies can be easily false negative so
that the tumor localization might not be very exact. These
methods can then be combined with the dynamic contrast-
enhanced magnetic resonance imaging, since ﬁrst studies
haveshownthatitmaybeanaccuratetechniquefordetecting
and quantifying intracapsular transition or peripheral zone
tumor foci greater than 0.2cc [40].
6. Conclusion
Theresultsofourstudyshowedthatbothdiﬀusion-weighted
Imaging and MR spectroscopy should be considered as
an additional and complementary tool to the T2 weighted
MRI not only for detecting prostate cancer, but also for8 Radiology Research and Practice
guidingmorespeciﬁcbiopsieswithouttakingseveralsamples
from the organ. The combination of these methods can
improve the speciﬁcity and may prevent uncomfortable as
well as painful biopsies for patients. The DWI is furthermore
advantageous over the present examination methods, such
as the MR spectroscopy, regarding the considerably shorter
examination time (approximatly 5 minutes in case of this
study) and the correlation with the Gleason score.
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